Clinical Trials
2 trialsNCT00482053 2018-05-14
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Stanford University
Phase 2 Terminated
NCT00725062 2017-11-29
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated